Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0328 for Parkinson's Disease Mild Cognitive Impairment (PD-MIND)
NCT04810104Phase 2Withdrawn
- Sponsor
- King's College London
- Start
- Oct 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of AZD0328 in Mild Cognitive Impairment in Parkinson’s Disease (PD-MCI), sponsored by King's College London. Planned start Oct 2022; status: withdrawn.
02
Drugs
AZD0328
03
Conditions
Mild Cognitive Impairment in Parkinson’s Disease (PD-MCI)
Beyond the preview
Go deeper on NCT04810104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04810104.